UK-based discovery technology company Selcia operates two divisions, Selcia Discovery and Selcia Radiolabelling, which together support pharma and biotech drug discovery development. Selcia Discovery medicinal chemists apply synthetic chemistry to solve problems in biology, pharmacology and medicine with an approach that can be tailored to the specialist needs of academic institutions and small biotechs. Simon Saxby, Selcia's CEO, describes the company's exepertise and business model, and explains how it sees the future for medicinal chemistry in the current drug discovery arena.

The full article can be viewed in the sp2 Interactive March/April issue pp 16-18 via this link.